SOURCE: Research and Markets

Research and Markets

February 15, 2016 11:34 ET

Neurotech Industry 2015-2016 Report: Drugs, Biologics, Stem Cells, Devices and Diagnostics for the Brain and Nervous System

DUBLIN, IRELAND--(Marketwired - February 15, 2016) -  Research and Markets has announced the addition of NeuroInsights's new report "Neurotech Industry 2015-2016 Report: Drugs, Biologics, Stem Cells, Devices and Diagnostics for the Brain and Nervous System" to their offering.

Now in its 11th year, The Neurotechnology Industry 2015-2016 Report is an expanded and updated 650 page report of brain and nervous system markets and treatments. It is the only publication to provide a comprehensive pipeline and market analysis to help investors, companies and entrepreneurs easily identify opportunities, understand the competitive landscape, determine risks and understand the dynamics of rapidly changing CNS markets.

The report includes detailed information on products in development globally for over 20 indications at 800 companies including Alzheimer's, addiction, ALS, anxiety, depressive disorders, epilepsy, migraine, mild cognitive impairment, Huntington's, multiple sclerosis, obesity, pain, Parkinson's, schizophrenia, age-related macular degeneration, sensory disorders, sleep disorders, traumatic brain injury and stroke.

Key Topics Covered:

  • More than 500 profiles of public and private neurotech companies including drugs, devices and diagnostics
  • Pipelines and market analysis for 20 brain and nervous system illnesses including: addiction, Alzheimer's disease, anxiety, attention disorders, depression, epilepsy, hearing loss, insomnia, mild cognitive impairment, migraine, multiple sclerosis, obesity, pain, Parkinson's disease, retinal disorders, schizophrenia, stroke, and traumatic brain injury
  • Top neurotech investors, venture capital firms, and venture capital trends (1999-Q12015)
  • Neurotech IPOs (2004-Q12015), M&A (2004-Q12015), Partnering and Licensing deals (2005-Q12015) and public neurotech stock performance
  • Analysis of biological basis, current treatment options, and emerging therapeutic strategies
  • Analysis of compounds, cell therapies and devices in clinical trials (and abandoned) by company, mechanism of action and stage of development for each indication
  • Global and US market size, worldwide revenues for each indication
  • Extensive discussion of specific technological, demographic, regulatory and intellectual property trends

Companies Mentioned - Partial List

  • 23andMe
  • 454 Life Sciences
  • 7TM Pharma
  • AAVLife
  • AbaStar MDx
  • Abbott
  • AbbVie
  • Abiogen
  • Ablynx
  • AB Science
  • ABT Molecular Imaging
  • Acadia Pharmaceuticals
  • Accera
  • Accorda Therapeutics
  • AccSys Technology
  • Accuray
  • AcelRx
  • Achelios Therapeutics
  • AC Immune
  • Acorda
  • Acorda Therapeutics
  • Actavis
  • Actelion
  • Active Biotech
  • Acumen Pharmaceuticals
  • Acura

Report Structure:

1: Executive Summary

2: Trends and Drivers

3: Neuropharmaceutical Sector

4: Stem Cells and Neuroregeneration

5: Neurodevice Sector

6: Neurodiagnostics Sector

7: Private Neurotechnology Investment

8: Public Neurotechnology Investment

9: Neurotechnology Research Centers

10: Leading Neurotechnology Regions

11: Company Profiles

12: Index

For more information visit

Image Available:

Contact Information

  • Research and Markets
    Laura Wood
    Senior Manager

    For E.S.T Office Hours Call 1-917-300-0470
    For U.S./CAN Toll Free Call 1-800-526-8630
    For GMT Office Hours Call +353-1-416-8900

    U.S. Fax: 646-607-1907
    Fax (outside U.S.): +353-1-481-1716